Portal de Periódicos da CAPES

Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?

2024; Dustri-Verlag; Volume: 8; Issue: 1 Linguagem: Inglês

10.5414/alx02460e

2512-8957

Ludger Klimek, Ulrike Förster‐Ruhrmann, Heidi Olze, Achim Beule, Adam Chaker, Jan Hagemann, Tilman Huppertz, Thomas K. Hoffmann, Stefan Dazert, Thomas Deitmer, Sebastian Strieth, Holger Wrede, Wolfgang Schlenter, H.‐J. Welkoborsky, Barbara Wollenberg, Sven Becker, Fredericke Bärhold, Felix Klimek, Ingrid Casper, Jaron Zuberbier, Claudia Rudack, Mandy Cuevas, Constantin A. Hintschich, Orlando Guntinas‐Lichius, Timo Stöver, Christoph Bergmann, Pascal Werminghaus, Oliver Pfaar, Jan Gosepath, Moritz Gröger, Caroline Beutner, Martin Laudien, Rainer Weber, Tanja Hildebrand, Anna Sophie Hoffmann, Claus Bachert,

Asthma and respiratory diseases

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL-5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control. While national and international recommendations exist for the use of mepolizumab in CRSwNP, it has not yet been adequately specified how this therapy should be monitored, what follow-up documentation is necessary, and when it should be discontinued if necessary.